Your browser doesn't support javascript.
loading
[Evolution of the use of antidepressants, anxiolytics and hypnotics in Valencia. Period 2000-2010]. / Evolución de la utilización de antidepresivos, ansiolíticos e hipnóticos en la Comunitat Valenciana. Período 2000-2010.
Sempere Verdú, Ermengol; Salazar Fraile, José; Palop Larrea, Vicente; Vicens Caldentey, Caterina.
Afiliação
  • Sempere Verdú E; Médico de familia, Centro de Salud de Paterna, Paterna, Valencia, España. Electronic address: meresempere@gmail.com.
  • Salazar Fraile J; Psiquiatra, Centro de Salud de Paterna, Paterna, Valencia, España.
  • Palop Larrea V; Médico de familia, Subdirección Asistencial Departamento de Salud de la Ribera, Alzira, Valencia, España.
  • Vicens Caldentey C; Médico de familia, Centro de Salud Son Vileta, Palma de Mallorca, Islas Baleares, España.
Aten Primaria ; 46(8): 416-25, 2014 Oct.
Article em Es | MEDLINE | ID: mdl-24559729
ABSTRACT

OBJECTIVE:

To describe the evolution in the use of antidepressants (AD), anxiolytics (A) and hypnotics (H) in the Comunitat Valenciana (CV) between 2000 and 2010, their expenditure, and the cost of the defined daily dose (DDD).

DESIGN:

Retrospective observational study.

SETTING:

Prescriptions covered by the health public service of the CV during the period 2000-2010. MEASUREMENTS Consumption of the therapeutic groups N06A (antidepressants), N05B (anxiolytics) and N05C (hypnotics) from the pharmacy database of the public Valencian Health Agency measured in defined daily dose per 1.000 inhabitants.

RESULTS:

During the period of study the use of AD increased by 81.2% and A and H, 11.7%. Selective serotonin reuptake inhibitors were the most prescribed AD and Selective serotonin and norepinephrine reuptake inhibitors experienced the higher rise (386.8%). The increase of escitalopram was 1.013%. Lorazepam, alprazolam and diazepam, accounted for the 80.4% of the anxyolitics, and lormetazepam and zolpidem the 88.7% of the hypnotics. The expenditure rise of AD was by 78.2% and that of the A and H was 14.5%; the cost of the DDD of both decreased by 29%.

CONCLUSIONS:

Antidepressant utilization has experienced a remarkable rise between 2000 and 2010 while that of A and H has been mild even though they are still more consumed than AD. In spite of the reduction of the DDD cost in both therapeutic groups, the whole expenditure on AD in the CV is still growing.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ansiolíticos / Uso de Medicamentos / Hipnóticos e Sedativos / Antidepressivos Tipo de estudo: Observational_studies Limite: Humans País como assunto: Europa Idioma: Es Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ansiolíticos / Uso de Medicamentos / Hipnóticos e Sedativos / Antidepressivos Tipo de estudo: Observational_studies Limite: Humans País como assunto: Europa Idioma: Es Ano de publicação: 2014 Tipo de documento: Article